[Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults].
K V ZhdanovO V MaltsevK V KasyanenkoK V KozlovV S SukachevN I LvovV V SharabkhanovA A LitvinovPublished in: Terapevticheskii arkhiv (2023)
Riamilovir has shown clinical efficacy and a good safety profile in in both treatment regimens. The dosage regimen of 1250 mg per day led to more significant clinical effects and to 100% elimination of ARVI pathogens in the study group by the 6th day of hospitalization.